1-(1,2-dihydroacenaphthylen-1-yl)piperidin-4-one | 228246-88-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-(1,2-dihydroacenaphthylen-1-yl)piperidin-4-one
• 英文别名: 1-(acenaphthen-1-yl)-piperidin-4-one
• CAS: 228246-88-6
• 化学式: C₁₇H₁₇NO
• 分子量: 251.328
• InChiKey: QBTZALYOZZYCLX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(1,2-dihydroacenaphthylen-1-yl)piperidin-4-one 在 sodium tetrahydroborate 、 甲酸 、 乙酸酐 、 溶剂黄146 、 原甲酸三乙酯 作用下， 生成 8-acenaphthen-1-yl-1-(4-fluoro-phenyl)-1,3,8-triaza-spiro[4.5]decan-4-one
  参考文献：
  名称：

  8-Acenaphthen-1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as orphanin FQ receptor agonists

  摘要：

  A series of 8-acenaphthen-1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one derivatives 1 was studied with respect to the binding affinity for the orphanin FQ (OFQ) and opioid (mu, kappa, delta) receptors. The influence of stereochemistry as well as the substitution pattern of the phenyl-ring in position 1 on the affinity for the orphanin FQ receptor and selectivity to opioid (mu, kappa, delta) receptors is discussed. The most interesting compound Ic was tested for its anxiolytic-like properties in vivo. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00385-6
• 作为产物：
  描述：

  1-羟基二氢苊 在 platinum(IV) oxide 叠氮磷酸二苯酯 、 氢气 、 potassium carbonate 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 乙醇 、 甲苯 为溶剂， 生成 1-(1,2-dihydroacenaphthylen-1-yl)piperidin-4-one
  参考文献：
  名称：

  8-Acenaphthen-1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as orphanin FQ receptor agonists

  摘要：

  A series of 8-acenaphthen-1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one derivatives 1 was studied with respect to the binding affinity for the orphanin FQ (OFQ) and opioid (mu, kappa, delta) receptors. The influence of stereochemistry as well as the substitution pattern of the phenyl-ring in position 1 on the affinity for the orphanin FQ receptor and selectivity to opioid (mu, kappa, delta) receptors is discussed. The most interesting compound Ic was tested for its anxiolytic-like properties in vivo. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00385-6

文献信息

• PROCESS FOR PREPARING 1-(4-PIPERIDINYL)BENZIMIDAZOLONE DERIVATIVES
  申请人：Iwamura Hiroshi

  公开号：US20110295013A1

  公开（公告）日：2011-12-01

  Provision of an industrial method of producing a 1-(4-piperidinyl)benzimidazolone derivative in a high yield at a low cost. A production method of 1-(4-piperidinyl)benzimidazolone derivative (1) or a salt thereof according to the following steps. [step 1] a step of subjecting a piperidone compound (2) and an aniline compound (3) to a reductive amination reaction to give to a compound (4) [step 2] a step of reacting the compound (4) with di-t-alkyl dicarbonate or N,N′-disuccinimidyl carbonate to give the 1-(4-piperidinyl)benzimidazolone derivative (1) wherein R 1 is optionally substituted alkyl or an optionally substituted cyclic group, and R 2 is optionally substituted alkyl, optionally substituted alkenyl or optionally substituted aryl.

  提供一种工业方法，以低成本高产率生产1-(4-哌啶基)苯并咪唑酮衍生物。根据以下步骤生产1-(4-哌啶基)苯并咪唑酮衍生物（1）或其盐。[步骤1] 将哌啶酮化合物（2）和苯胺化合物（3）经还原胺化反应得到化合物（4）的步骤[步骤2] 将化合物（4）与二叔丁基二碳酸酯或N,N'-二琥珀酰亚胺碳酸酯反应，得到1-(4-哌啶基)苯并咪唑酮衍生物（1）其中R1可选地为取代烷基或取代环烷基，R2可选地为取代烷基、取代烯烃基或取代芳基。
• Remedy for sleep disturbance
  申请人：Teshima Koji

  公开号：US20050119308A1

  公开（公告）日：2005-06-02

  The present invention has been made based on the finding that a compound acting on the ORL-1 receptor as an agonist acts as a non-photic entrainment factor, and advances the circadian rhythm phase, and provides a novel therapeutic agent for a sleep disorder such as circadian rhythm sleep disorder, more particularly, an agent for the prophylaxis and/or treatment of a sleep disorder, which contains an ORL-1 receptor agonist, and a novel compound useful as such agent for the prophylaxis and/or treatment.

  本发明是基于发现得出的，即作用于ORL-1受体的化合物作为激动剂时，作为非光周期性调节因子，可以提前昼夜节律阶段，并提供一种新的治疗药物，用于治疗睡眠障碍，如昼夜节律睡眠障碍，更具体地说，是一种用于预防和/或治疗睡眠障碍的药物，其中包含ORL-1受体激动剂，并提供了一种作为该药物预防和/或治疗的有用化合物。
• HETEROCYCLIC-SUBSTITUTED PIPERIDINE COMPOUNDS AND THE USES THEREOF
  申请人：Brown Kevin C.

  公开号：US20100022519A1

  公开（公告）日：2010-01-28

  The invention relates to Heterocyclic-Substituted Piperidine Compounds, compositions comprising an effective amount of a Heterocyclic-Substituted Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Heterocyclic-Substituted Piperidine Compound.

  本发明涉及杂环取代哌啶化合物，包括含有有效量的杂环取代哌啶化合物的组合物和治疗或预防疾病的方法，例如疼痛，通过向需要治疗的动物施用有效量的杂环取代哌啶化合物。
• BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF
  申请人：Nakano Masakazu

  公开号：US20100120841A1

  公开（公告）日：2010-05-13

  Provided is an ORL-1 receptor agonist having improved bioavailability based on superior metabolic stability and strong and high selectivity, as compared to conventional compounds. A compound represented by the formula (I) wherein each symbol is as defined in the claims.

  提供了一种基于卓越的代谢稳定性和强大的高选择性，相比传统化合物具有改善生物利用度的ORL-1受体激动剂。该化合物由公式（I）表示，其中每个符号如权利要求中所定义。
• Spiro(piperidine-4,1'-pyrrolo(3,4-c)pyrrole)
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0963987A2

  公开（公告）日：1999-12-15

  The present invention relates to compounds of the general formula    wherein the substituents are described in the application and to pharmaceutically acceptable acid addition salts thereof. The compound of the invention are useful in the treatment of diseases related to the orphanin FQ (OFQ) receptor, which include psychiatric, neurological and physiological disorders, such as anxiety and stress disorders, depression, trauma, memory loss due to Alzheimer's disease or other dementias, deficits in cognition and leaning, epilepsy and convulsions, acute and/or chronic pain conditions, and symptoms of addictive drug withdrawal, control of water balance, Na+ excretion, arterial blood pressure disorders and metabolic disorders such as obesity.

  本发明涉及通式为 其中的取代基见本申请所述，以及其药学上可接受的酸加成盐。 本发明的化合物可用于治疗与孤儿素 FQ（OFQ）受体有关的疾病，这些疾病包括精神、神经和生理疾病，如焦虑和应激障碍、抑郁症、创伤、阿尔茨海默病或其他痴呆症导致的记忆丧失、认知和精益功能障碍、癫痫和抽搐、急性和/或慢性疼痛病症、成瘾性药物戒断症状、水平衡控制、Na+排泄、动脉血压紊乱和代谢紊乱，如肥胖。